Robin Emsley, MBChB, MMed, FCPsych, MD

Tianeptine for Elderly with Recurrent MDD

July 3, 2018

Read a randomized control trial evaluating tianeptine's efficacy in patients 65 and older with recurrent major depressive disorder (MDD).

Robin Emsley, Antti Ahokas, Aldo Suarez, et al

Original Research

Schizophrenia Relapse After Antipsychotic Discontinuation

June 19, 2018

High rates of schizophrenia symptom recurrence after antipsychotic treatment discontinuation are are thought to be due to withdrawal-related phenomena rather than illness recurrence. This post hoc analysis examines results...

Robin Emsley, Isaac Nuamah, Srihari Gopal, et al

Original Research

Symptom Recurrence Following Intermittent Treatment in First-Episode Schizophrenia Successfully Treated for 2 Years: A 3-Year Open-Label Clinical Study

April 15, 2012

Robin Emsley, Petrus P. Oosthuizen, Liezl Koen, et al

Original Research

Agomelatine Prevents Relapse in Patients With Major Depressive Disorder Without Evidence of a Discontinuation Syndrome: A 24-Week Randomized, Double-Blind, Placebo-Controlled Trial

August 11, 2009

Guy M. Goodwin, Robin Emsley, Sandra Rembry, et al

Original Research

A 24-Week, Multicenter, Open-Label, Randomized Study to Compare Changes in Glucose Metabolism in Patients With Schizophrenia Receiving Treatment With Olanzapine, Quetiapine, or Risperidone

April 7, 2009

John W. Newcomer, Robert E. Ratner, Jan W. Eriksson, et al

Original Research

Remission in First-Episode Psychosis: Predictor Variables and Symptom Improvement Patterns

November 15, 2006

Robin Emsley, Piet P. Oosthuizen, Martin Kidd, et al

Original Research

A Single-Blind, Randomized Trial Comparing Quetiapine and Haloperidol in the Treatment of Tardive Dyskinesia

May 1, 2004

Robin Emsley, H. Jadri Turner, Juan Schronen, et al

Robin Emsley, MBChB, MMed, FCPsych, MD

Tianeptine for Elderly with Recurrent MDD

Schizophrenia Relapse After Antipsychotic Discontinuation

Symptom Recurrence Following Intermittent Treatment in First-Episode Schizophrenia Successfully Treated for 2 Years: A 3-Year Open-Label Clinical Study

Agomelatine Prevents Relapse in Patients With Major Depressive Disorder Without Evidence of a Discontinuation Syndrome: A 24-Week Randomized, Double-Blind, Placebo-Controlled Trial

A 24-Week, Multicenter, Open-Label, Randomized Study to Compare Changes in Glucose Metabolism in Patients With Schizophrenia Receiving Treatment With Olanzapine, Quetiapine, or Risperidone

Remission in First-Episode Psychosis: Predictor Variables and Symptom Improvement Patterns

A Single-Blind, Randomized Trial Comparing Quetiapine and Haloperidol in the Treatment of Tardive Dyskinesia

ELSEWHERE:

FOLLOW US:

Robin Emsley, MBChB, MMed, FCPsych, MD

Tianeptine for Elderly with Recurrent MDD

Schizophrenia Relapse After Antipsychotic Discontinuation

Symptom Recurrence Following Intermittent Treatment in First-Episode Schizophrenia Successfully Treated for 2 Years: A 3-Year Open-Label Clinical Study

Agomelatine Prevents Relapse in Patients With Major Depressive Disorder Without Evidence of a Discontinuation Syndrome: A 24-Week Randomized, Double-Blind, Placebo-Controlled Trial

A 24-Week, Multicenter, Open-Label, Randomized Study to Compare Changes in Glucose Metabolism in Patients With Schizophrenia Receiving Treatment With Olanzapine, Quetiapine, or Risperidone

Remission in First-Episode Psychosis: Predictor Variables and Symptom Improvement Patterns

A Single-Blind, Randomized Trial Comparing Quetiapine and Haloperidol in the Treatment of Tardive Dyskinesia

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles